GreenLight Biosciences Holdings (GRNA)

Market Cap	70.34M
Revenue (ttm)	6.78M
Net Income (ttm)	-167.06M
Shares Out	151.55M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	417,054
Open	0.443
Previous Close	0.448
Day's Range	0.421 - 0.470
52-Week Range	0.317 - 11.340
Beta	1.48
Analysts	Buy
Price Target	4.85 (+945.03%)
Earnings Date	Mar 28, 2023

About GRNA

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 280
• Stock Exchange: NASDAQ
• Ticker Symbol: GRNA

Financial Performance

In 2022, GRNA's revenue was $6.78 million, an increase of 325.08% compared to the previous year's $1.60 million. Losses were -$167.06 million, 48.7% more than in 2021.

Analyst Forecast

According to 8 analysts, the average rating for GRNA stock is "Buy." The 12-month stock price forecast is $4.85, which is an increase of 945.03% from the latest price.

Price Target

$4.85

(945.03% upside)

Analyst Consensus: Buy